Lipoprotein lipase deficiency - Rare or common?

Cardiovascular Drugs and Therapy

Volumn 16, Issue 4, 2002, Pages 283-287

  Evans, Valerie ^a   Kastelein, John J P ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disease; Chylomicronemia; Lipoprotein lipase; LPL deficiency

Indexed keywords

ANTIOXIDANT; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATALYSIS; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; DIET SUPPLEMENTATION; DIETARY INTAKE; ENVIRONMENTAL FACTOR; EXERCISE; GENE MUTATION; GENE THERAPY; HEALTH BEHAVIOR; HEREDITY; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; LIFESTYLE; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; TREATMENT INDICATION;

CARDIOVASCULAR DISEASES; CHYLOMICRONS; DIET THERAPY; GENE THERAPY; HUMANS; LIPOPROTEIN LIPASE; LIPOPROTEINS; MUTATION; RISK FACTORS;

EID: 0036983822     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021721707639     Document Type: Conference Paper

References (30)

1. American Heart Association. 2002 Heart and Stroke Statistical Update. Available from: http://www.americanheart.org
2. Mead JR, Cryer A, Ramji DP. Lipoprotein lipase, a key role in atherosclerosis? FEBS Lett 1999;462(1-2):1-6.
3. Hayden M, Henderson HE. The molecular biology and genetics of human lipoprotein lipase. In: Betteridge DJ, Illingworth DR, Shepherd J, eds. Lipoproteins in Health and Disease. London: Oxford University Press, 1999:247-260.
4. Brunzell J. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: Scriver C, Baudet A, Sly W, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. 7th ed. New York: McGraw-Hill, 1995:1913-1932.
5. Beisiegel U, Weber W, Bengtsson-Olivecrona G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc Nat Acad Sci 1991;88:8342-8346.
6. Olivecrona T, Olivecrona G. Lipoprotein and hepatic lipase in lipoprotein metabolism. In: Betterdige DJ, Illingworth DR, Shepherd J, eds. Lipoproteins in Health and Disease. London: Arnold Publishers, 1999:223-246.
7. Goldberg IJ, Merkel M. Lipoprotein lipase: Physiology, biochemistry, and molecular biology. Front Biosci 2001;6:D388-405. Review.
8. Mulder M, Lombardi P, Jansen H, van Berkel TJ, Frants RR, Havekes LM. Heparan sulfate proteoglycans are invovled in the lipoprotein lipase-mediated enhancement of the cellular binding of very low density and low density lipoproteins. Biochem Biophys Res Commun 1992;185(2):582-587.
9. Santamarina-Fojo S. The familial chylomicronemia syndrome. Endocrinol Metab Clin North Am 1998;27(3):551-567, viii.
10. Gilbert B, Rouis M, Griglio S, de Lumley L, Laplaud P-M. Lipoprotein lipase (LPL) deficiency: A new patient homozygote for the preponderant mutation Gly188Glu in the human LPL gene and review of reported mutations: 75% are clustered in exon 5 and 6. Ann Genet 2001;44:25-32.
11. Wittekoek ME, Primstone SN, Reymer PWA, et al. A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia. Circulation 1998;97:729-735.
12. Wittekoek ME, Moll E, Pimstone SN, et al. A frequent mutation in the lipoprotein lipase gene (D9N) deteriorates the biochemical and clinical phenotype of familial hypercholesterolemia. Aterioscler Thromb Vasc Biol 1999;19:2708-2713.
13. Nordestgaard BG, Abildgaard S, Wittrup HH, Steffensen R, Jensen G, Tybjaerg-Hansen A. Heterozygous lipoprotein lipase deficiency: Frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation 1997;96(6):1737-1744.
14. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3(2):213-219.
15. Reymer PW, Gagne E, Groenemeyer BE, et al. A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nat Genet 1995;10(1):28-34.
16. Jukema JW, van Boven AJ, Groenemeijer B, et al. The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study. Circulation 1996;94(8):1913-1918.
17. Hokanson JE. Lipoprotein lipase gene variants and risk of coronary disease: A quantitive analysis of population-based studies. Int J Clin Lab Res 1997;27(1):24-34.
18. Wittrup HH, Tybjaerg-Hansen A, Abildgaard S, Steffensen R, Schnohr P, Nordestgaard BG. A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. J Clin Invest 1997;99(7):1606-1613.
19. Kastelein JJP, Ordovas JM, Wittekoek ME, et al. Two common mutations (D9N, N291S) in lipoprotein lipase: A cummulative analysis of their influence on plasma lipids and lipoproteins in men and women. Clin Genet 1999;56:297-305.
20. Sing K, Ballantyne CM, Ferlic L, et al. Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study. Atherosclerosis 1999;144(2):435-442.
21. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999;99(22):2901-2907.
22. Wittrup HH, Nordestgaard BG, Sillesen H, Schnohr P, Tybjaerg-Hansen A. A common mutation in lipoprotein lipase confers a 2-fold increase in risk of ischemic cerebrovascular disease in women but not in men. Circulation 2000;101(20):2393-2397.
23. van Bockxmeer FM, Liu Q, Mamotte C, Burke V, Taylor R. Lipoprotein lipase D9N, N291S, S447X polymorphisms: Their influence on premature coronary artery disease and plasma levels. Atherosclerosis 2001;157:123-129.
24. Funke H, Assmann G. The low down on lipoprotein lipase. Nat Genet 1995;10:6-7.
25. Benlian P, De Gennes JL, Foubert L, Zhang H, Gagne SE, Hayden M. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 1996;335(12):848-854.
26. Jemaa R, Fumeron F, Poirier O, et al. Lipoprotein lipase gene polymorphisms: Associations with myocardial infarction and lipoprotein levels, the ECTIM study. Etude Cas Temoin sur l'Infarctus du Myocarde. J Lipid Res 1995;36(10):2141-2146.
27. Wittrup HH, Tybjaerg-Hansen A, Steffensen R, et al. Mutations in the lipoprotein lipase gene associated with ischemic heart disease in men. The Copenhagen city heart study. Arterioscler Thromb Vasc Biol 1999;19(6):1535-1540.
28. Heaney AP, Sharer N, Rameh B, Braganza JM, Durrington PN. Prevention of recurrent pancreatitis in familial lipoprotein lipase deficiency with high-dose antioxidant therapy. J Clin Endocrinol Metab 1999;84(4):1203-1205.
29. Larson PJ, High KA. Gene therapy for hemophilia B: AAV-mediated transfer of the gene for coagulation factor IX to human muscle. Adv Exp Med Biol 2001;489:45-57
30. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000;24(3):257-261.